Equities

Alzamend Neuro Inc

Alzamend Neuro Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)1.69
  • Today's Change-0.06 / -3.43%
  • Shares traded145.21k
  • 1 Year change-95.10%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 19-Sep-24
Select bar for recommendation details.
Recommendations19-Sep-24
Buy0
Outperform1
Hold1
Sell0
Strong Sell0

Share price forecast in USD

The one analyst offering a 12 month price target expects Alzamend Neuro Inc share price to rise to 50.00 in the next year from the last price of 1.69.
High2,858.6%50.00
Med2,858.6%50.00
Low2,858.6%50.00

Earnings history & estimates in USD

On Sep 11, 2024, Alzamend Neuro Inc reported 1st quarter 2025 losses of -1.25 per share. This result exceeded the -2.38 consensus loss of the one analyst covering the company and exceeded last year's 1st quarter results by 79.17%.
The next earnings announcement is expected on Dec 13, 2024.
Average growth rate-30.09%
Alzamend Neuro Inc reported annual 2024 losses of -14.70 per share on Jul 30, 2024.
Average growth rate+13.76%
More ▼

Revenue history & estimates in USD

Alzamend Neuro Inc did not report revenues for the 1st quarter 2025. However, during the 1st quarter of the prior year the company reported revenues of 0.00.
Average growth rate0.00%
Alzamend Neuro Inc did not report revenues for the full year 2024. However, during the prior year the company reported revenues of 0.00.
Average growth rate0.00%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.